Pharma Reviews: Targeting of China is not a great idea

Or was China behaving like a bully and it is time for India to send a tough ... But most of the Active Pharmaceutical Ingredients (API) or bulk drugs ...
Read more: Targeting of China is not a great idea

Pharma Reviews: Domestic growth: Fresh challenge for pharma companies

After a subdued April that saw Indian pharma market post its weakest growth in last two years, May was only marginally better. April saw a tepid 3.5% ...
Read more: Domestic growth: Fresh challenge for pharma companies

Pharma Reviews: Why Hand over a National Asset to Foreign MNCs?

The Indian pharmaceutical industry is a national asset built through supportive public policy in a bygone era. It continues to be widely hailed as a ...
Read more: Why Hand over a National Asset to Foreign MNCs?

Pharma Reviews: Big pharma ready to swallow the Brexit pill

LONDON: Pharmaceutical companies have survived largely unscathed from the turmoil that has gripped virtually every other sector in the stock market ...
Read more: Big pharma ready to swallow the Brexit pill

US FDA News: FDA clears first test to detect specific genetic markers for certain antibiotic-resistant bacteria directly from clinical specimens

The U.S. Food and Drug Administration today cleared for marketing the Xpert Carba-R Assay, an infection control aid that tests patient specimens to detect specific genetic markers associated with bacteria that are resistant to Carbapenem antibiotics. Carbapenem antibiotics are widely used in hospitals to treat severe infections. These resistant organisms are commonly referred to as Carbapenem-resistant Enterobacteriaceae, or CRE, and have been reported in almost all states within the U.S.
Read more: FDA clears first test to detect specific genetic markers for certain antibiotic-resistant bacteria directly from clinical specimens

US FDA News: FDA approves implantable device that changes the shape of the cornea to correct near vision

The U.S. Food and Drug Administration today approved the Raindrop Near Vision Inlay, a device implanted in the cornea (the clear, front surface) of one eye to improve near vision in certain patients with presbyopia. It is the second FDA-approved implantable corneal device for correction of near vision in patients who have not had cataract surgery and the first implantable device that changes the shape of the cornea to achieve improved vision.
Read more: FDA approves implantable device that changes the shape of the cornea to correct near vision

US FDA News: HeartWare Ventricular Assist Device (HVAD) Batteries by HeartWare Inc.: Class I Recall - Premature Power Depletion

Batteries may lose power prematurely due to faulty cells.
Read more: HeartWare Ventricular Assist Device (HVAD) Batteries by HeartWare Inc.: Class I Recall - Premature Power Depletion

Pharma Reviews: Targeting of China is not a great idea

China is a vital piece of the Indian pharma story. If China ... and other raw materials, it will affect India's pharma industry and bring it almost to a halt.
Read more: Targeting of China is not a great idea

US FDA News: FDA requests additional information to address data gaps for consumer hand sanitizers

The U.S. Food and Drug Administration today issued a proposed rule requesting additional scientific data to support the safety and effectiveness of certain active ingredients used in topical consumer antiseptic rubs (including hand sanitizers) marketed over-the-counter (OTC). The FDA’s request for more data is intended to help the agency ensure that regular use of these products does not present unknown safety and efficacy concerns, and does not mean the FDA believes these products are ineffective or unsafe.
Read more: FDA requests additional information to address data gaps for consumer hand sanitizers

US FDA News: Statement from FDA Commissioner Robert Califf, M.D. announcing the acting director of the FDA Oncology Center of Excellence

The FDA is honored to be an integral part of the Vice President’s National Cancer Moonshot Initiative (“Cancer Moonshot”), which calls on the agency to leverage the combined skills of regulatory scientists and reviewers with expertise in drugs, biologics and devices to create the Oncology Center of Excellence (OCE). The OCE will expedite the development of novel combination products and support an integrated approach to tackle this devastating disease that touches so many American families.
Read more: Statement from FDA Commissioner Robert Califf, M.D. announcing the acting director of the FDA Oncology Center of Excellence

Pharma Reviews: Industry welcomes Centres call to allow 74% FDI in brownfield pharma projects

This will now ensure a smooth passage for the big pharma cos or financial investors to invest in Indian drug companies through M&A route by buying ...
Read more: Industry welcomes Centres call to allow 74% FDI in brownfield pharma projects

Pharma Reviews: Karnataka pharma industry in wait & watch mode on Brexit impact

Some members of the Karnataka pharma industry feel that Brexit can affect their ... are opportunities to be converted for Indian pharma manufacturers.
Read more: Karnataka pharma industry in wait & watch mode on Brexit impact

Pharma Reviews: 'OSMC trying to ruin State pharma MSMEs'

BHUBANESWAR: The Utkal Pharmaceutical Manufacturers' Association has accused Odisha State Medical Corporation (OSMC) of dumping the ...
Read more: 'OSMC trying to ruin State pharma MSMEs'

US FDA News: FDA approves Epclusa for treatment of chronic Hepatitis C virus infection

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin. Epclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.
Read more: FDA approves Epclusa for treatment of chronic Hepatitis C virus infection

US FDA News: Federal Court orders California soy company to cease production due to food safety violations

The U.S. District Court for the Eastern District of California entered a consent decree of permanent injunction on Friday, June 24, 2016, between the U.S. Food and Drug Administration and Wa Heng Dou-Fu & Soy Sauce Corporation requiring the business to immediately cease manufacturing and distributing food until it comes into compliance with federal food safety laws.
Read more: Federal Court orders California soy company to cease production due to food safety violations

Pharma Reviews: Kwality Pharmaceuticals coming with an IPO to raise upto Rs 6.21 crore

The Indian pharmaceuticals market is the third largest in terms of volume and thirteen largest in terms of value. Branded generics dominate the ...
Read more: Kwality Pharmaceuticals coming with an IPO to raise upto Rs 6.21 crore

Pharma Reviews: The new pharma FDI policy undermines Indian generics, which may make drugs more expensive

It will only allow capital flow from India to developed countries whose pharmaceutical industry is taking over key Indian companies to enter the generic ...
Read more: The new pharma FDI policy undermines Indian generics, which may make drugs more expensive

Pharma Reviews: USFDA nods to Indian drugs up 84% in 1 year

MUMBAI: Drug approvals given by the US Food and Drug Administration (USFDA) to Indian companies nearly doubled year-on-year, with littleknown ...
Read more: USFDA nods to Indian drugs up 84% in 1 year

Pharma Reviews: Andhra, Telangana lead in pharma exports, achieves

The two states contributed more than 30 per cent of India's total pharma exports. For the year 2014-15, the pharmaceutical exports from AP and TS ...
Read more: Andhra, Telangana lead in pharma exports, achieves

Pharma Reviews: Why Brexit isn't a reason to exit Indian equities

However, the pharmaceutical industry may not be impacted much as Britain accounts for just 5-6 % of India's pharmaceutical exports.
Read more: Why Brexit isn't a reason to exit Indian equities

Pharma Reviews: Indian pharma segment may not be impacted by Brexit

The Indian pharmaceutical segment is unlikely to be impacted adversely due to Britain's decision to move out of the European Union (EU) as the entire ...
Read more: Indian pharma segment may not be impacted by Brexit

Pharma Reviews: NCB to sensitize pharmaceutical industry on illegal use of chemicals

NCB to sensitize pharmaceutical industry on illegal use of chemicals. Apart from ... Just like the US, people in India too use such medicines as drugs.
Read more: NCB to sensitize pharmaceutical industry on illegal use of chemicals

Pharma Reviews: Be guardians of health

The Indian pharmaceutical industry globally ranks at the third position in terms ... Here there will be industrial pharmacists who perform different roles.
Read more: Be guardians of health

Pharma Reviews: Turning the heat on companies

Stocks of companies with exposure to the UK or the EU pummelled on ... Besides, while the exposure of large Indian pharma companies to the UK ...
Read more: Turning the heat on companies

Pharma Reviews: Sun Pharma staff stages protest inside Pride Hotel for pending salary!

Sun Pharmaceutical Industries Limited (an Indian Multinational Pharmaceutical Company) headquartered in Mumbai that manufactures and sells ...
Read more: Sun Pharma staff stages protest inside Pride Hotel for pending salary!

Pharma Reviews: Gujarat industries unclear about impact of Brexit

The impact seems to be on the negative side for pharma companies," said Viranchi Shah, vice-chairman, the Gujarat State Board, Indian Drug ...
Read more: Gujarat industries unclear about impact of Brexit

Pharma Reviews: So, who is virtually immune from Brexit carnage in India? Here's who and why ?

The domestic pharmaceutical industry is largely of the view that it will not feel the Brexit pinch even while some companies see a short-term limited ...
Read more: So, who is virtually immune from Brexit carnage in India? Here's who and why ?

Pharma Reviews: Pharma majors see minimal impact of breakaway decision

In fact, when it comes to the European Union, the number of big guns of the Indian pharma industry selling into the region becomes that much larger, ...
Read more: Pharma majors see minimal impact of breakaway decision

Pharma Reviews: Stocks with exposure to UK, Europe bear the brunt

Besides, while the exposure of large Indian pharma companies to the UK market may not be very significant, smaller players such as Dishman, Strides ...
Read more: Stocks with exposure to UK, Europe bear the brunt

Pharma Reviews: Ranbaxy whistle blower Dinesh Thakur suggests strict prosecution laws to fix drug industry

NEW DELHI: Dinesh Thakur, the famous whistle blower who highlighted data manipulation issues at top Indian drug maker Ranbaxy (now part of Sun ...
Read more: Ranbaxy whistle blower Dinesh Thakur suggests strict prosecution laws to fix drug industry

Pharma Reviews: Brexit to have limited impact on pharma industry: ICRA

India's total pharma exports in 2015-16 were USD 13 billion. Of these, EU accounted for USD 1.51 billion, UK (USD 469 million) and the US (USD 5.02 ...
Read more: Brexit to have limited impact on pharma industry: ICRA

Pharma Reviews: Sun Pharma bets on new products to boost US skincare products growth | Reuters

MUMBAI India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising ...
Read more: Sun Pharma bets on new products to boost US skincare products growth | Reuters

Pharma Reviews: Pharma sector to grow by 20% on relaxed FDI norms: Govt

At present, the country exports pharmaceutical goods to 205 countries and every five medicines or tablets consumed in the world are from India, he ...
Read more: Pharma sector to grow by 20% on relaxed FDI norms: Govt

Pharma Reviews: Fresh round of uncertainty for Indian pharma as the UK votes to leave EU

As far as Indian pharma is concerned, companies to watch would be Aurobindo Pharma, which has little over 20 per cent of business coming from ...
Read more: Fresh round of uncertainty for Indian pharma as the UK votes to leave EU

Pharma Reviews: Pharma sector to grow by 20% on relaxed FDI norms: Ananth Kumar

At present, the country exports pharmaceutical goods to 205 countries and every five medicines or tablets consumed in the world are from India, ...
Read more: Pharma sector to grow by 20% on relaxed FDI norms: Ananth Kumar

Pharma Reviews: Allowing 74% FDI in pharma sector may attract many MNCs to invest in India

The new Foreign Direct Investment (FDI) policy 2016 allowing 74 per cent FDI through automatic route in pharmaceutical industry will open up the ...
Read more: Allowing 74% FDI in pharma sector may attract many MNCs to invest in India

Pharma Reviews: FDI reforms: A lot of concerns remain

In 2015, India's total inward FDI stock was around $282 billion, while in ... The Indian pharma industry has built up an enviable reputation across the ...
Read more: FDI reforms: A lot of concerns remain

Pharma Reviews: India needs strict prosecution laws to fix drug regulatory system: Ranbaxy whistleblower Dinesh ...

India needs strict prosecution laws to fix drug regulatory system: Ranbaxy ... overhaul of rules governing the Indian pharmaceutical industry.
Read more: India needs strict prosecution laws to fix drug regulatory system: Ranbaxy whistleblower Dinesh ...

Pharma Reviews: Sun Pharma bets on new products to boost US skincare products growth

MUMBAI: India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising ...
Read more: Sun Pharma bets on new products to boost US skincare products growth

Pharma Reviews: Brexit: Road ahead of India

Indian pharma companies like Marksans Pharma, Emcure Pharma, etc and other Indian firms like Bharat Forge, Bharati Airtel, Motherson Sumi will ...
Read more: Brexit: Road ahead of India

Pharma Reviews: India's Sun Pharma bets on new products to boost US skincare products growth

India's largest drugmaker Sun Pharmaceutical Industries is banking on the launch of newer and more complex products to offset rising competition in ...
Read more: India's Sun Pharma bets on new products to boost US skincare products growth

Pharma Reviews: Mylan says Indian drug industry needs more transparency from FDA

Mylan president Rajiv Malik said, “The problem is there's a process, but there's no transparency about the process. There's a timeline but there's no ...
Read more: Mylan says Indian drug industry needs more transparency from FDA

Pharma Reviews: Pharma contract manufacturers hit as IPM slows down

... secretary general of the Indian Pharmaceutical Alliance (IPA), an umbrella body of domestic drug makers. Shah argued that this is because for some ...
Read more: Pharma contract manufacturers hit as IPM slows down

Pharma Reviews: Subramanian Swamy's views personal, govt has full confidence in Arvind Subramanian: Arun Jaitley

... the US should act against India to defend US Pharmaceuticals interests? ... I have; he supported Indian pharma industry in a hearing in US senate.
Read more: Subramanian Swamy's views personal, govt has full confidence in Arvind Subramanian: Arun Jaitley

Pharma Reviews: Govt's pharma FDI sop may hit affordable healthcare

... isn't compromised,” said Dilip G Shah, the secretary general of Indian Pharmaceutical Alliance (IPA) and the CEO of Vision Consulting Group.
Read more: Govt's pharma FDI sop may hit affordable healthcare

Pharma Reviews: Pharma exports cross 1 lakh cr mark

Hyderabad: Further consolidating India's position as a premier hub on the global pharmaceutical landscape, pharma exports from the country crossed ...
Read more: Pharma exports cross 1 lakh cr mark

Pharma Reviews: FDC drugs have several beneficial aspects that had brought relief to patients: Former DoP ...

He said FDC is a very big innovation in the pharmaceutical sector. ... “In spite of several problems, the pharma industry in India has grown so much.
Read more: FDC drugs have several beneficial aspects that had brought relief to patients: Former DoP ...

Pharma Reviews: 'India's share is hardly 10-12 per cent of the total (cleanroom consumables) market'

Cleanroom consumable products play a key role in pharma companies and the industry is growing rapidly. Sanjiv Marathe, Proprietor and CEO, ...
Read more: 'India's share is hardly 10-12 per cent of the total (cleanroom consumables) market'

Pharma Reviews: Alfa Laval holds leading global market position within its fields of expertise

For some types of industrial waste, e.g. pharma, pasteurisation of waste ... What is the average spend by the Indian pharma industry on waste water ...
Read more: Alfa Laval holds leading global market position within its fields of expertise

Pharma Reviews: 'MedTrix is proud to partner with large global pharma companies'

Tell us about your offerings for the global pharma sector? ... We are in talks with Indian pharma companies and we plan to leverage on Digital India ...
Read more: 'MedTrix is proud to partner with large global pharma companies'

Pharma Reviews: Rockwell Automation conducts life science symposium in Mumbai

Gopal Nair, Director, International Society for Pharmaceutical Engineering India Affiliate presented data on the Indian pharma growth story and ...
Read more: Rockwell Automation conducts life science symposium in Mumbai

Pharma Reviews: Switzerland-based Datwyler to invest 65 million Swiss franc in India by 2017

“We have been supplying products to Indian pharma injectable manufacturers over last 2 decades. Top 25 pharma companies in India and abroad are ...
Read more: Switzerland-based Datwyler to invest 65 million Swiss franc in India by 2017

Pharma Reviews: Karnataka to see more global investments as govt permits 74% FDI under automatic route for ...

In 2014-2015, Medreich-Meiji took over which is the first 100 per cent acquisition of a pharma enterprise by a Japanese company in India.
Read more: Karnataka to see more global investments as govt permits 74% FDI under automatic route for ...

Pharma Reviews: Pharma M&As: value creator or value destroyer?

Before we go into the drivers of M&A in the pharma industry, let's take a look at the M&A activity in 2015, both globally and in India. The cumulative ...
Read more: Pharma M&As: value creator or value destroyer?

Pharma Reviews: Higher cap in pharma sector raises questions

Indian Pharmaceutical Alliance's DG Shah feels the “acid test” for the government is in how the pharmaceutical landscape fares over the next three ...
Read more: Higher cap in pharma sector raises questions

Pharma Reviews: Pharma stocks climb up to 10.4 pc on FDI reforms

India is recognised as a major generic medicine hub of the world. The market size of the countrys pharma industry is estimated at over USD 20 billion.
Read more: Pharma stocks climb up to 10.4 pc on FDI reforms

Pharma Reviews: Govt relaxes FDI norms in civil aviation, defence, pharma

For the pharmaceuticals sector, the government relaxed the norms and ... The move assumes significance as FDI in the existing pharma companies has ... raised over some M and As of Indian pharma companies by foreign giants.
Read more: Govt relaxes FDI norms in civil aviation, defence, pharma

Pharma Reviews: FDI in pharma: No game changer, 'health security' worries still on the horizon

But Indian Pharmaceutical Alliance's DG Shah feels the “acid test” for the government would be in how the pharmaceutical landscape fares over the ...
Read more: FDI in pharma: No game changer, 'health security' worries still on the horizon

Pharma Reviews: Hot deals, foreign investors to breathe life into pharma sector

Industry experts believe that the government liberalising FDA norms in ... The Indian pharmaceutical industry is expected to touch USD 20 billion in ...
Read more: Hot deals, foreign investors to breathe life into pharma sector

Pharma Reviews: CIPMMA urges DCGI to provide prior information to industry about listing of drugs under 'banned ...

The Consortium of Indian Pharmaceutical Manufacturers & Marketers Association (CIPMMA) has urged the Drugs Controller General of India (DCGI) ...
Read more: CIPMMA urges DCGI to provide prior information to industry about listing of drugs under 'banned ...

Pharma Reviews: The Modi Government's New FDI Policy Will Hurt Indian Interests

The latest changes in foreign direct investment (FDI) norms in India have ... The Indian pharmaceutical industry is known for reverse engineering, ...
Read more: The Modi Government's New FDI Policy Will Hurt Indian Interests

Pharma Reviews: FDI is no talisman: The simplistic thinking of Narendra Modi and Manmohan Singh

If foreign pharma biggies can grab Indian pharma companies, which they will after this decision to allow 100% FDI in the pharma sector, it should be ...
Read more: FDI is no talisman: The simplistic thinking of Narendra Modi and Manmohan Singh

Pharma Reviews: New drugs fail to crack resistance and other top pharma news

Indian pharma market's (IPM) growth bounced backed to 10.2% year-on-year in May compared to 7% in April. IPM sales witnessed growth of 13.6% ...
Read more: New drugs fail to crack resistance and other top pharma news

Pharma Reviews: Modi govt surrendering to pressure of US pharma lobby, says Congress leader Anand Sharma

foreign direct investment, fdi, fdi in india, fdi defence, fdi food, ... On the pharma sector, he said FDI was permitted in greenfield projects where new ...
Read more: Modi govt surrendering to pressure of US pharma lobby, says Congress leader Anand Sharma

Pharma Reviews: FDI in pharma to boost M&As, PE investments, say experts

The pharmaceutical sector in India will register higher growth during the course of the next five years (22%) as compared to a CAGR of about 14% ...
Read more: FDI in pharma to boost M&As, PE investments, say experts

Pharma Reviews: A nascent Indian e-pharma sector already plagued by bias and harassment

Pharma has always been one of the hot sectors of the country attracting a lot of traction. India's pharmaceuticals industry is expected to account for ...
Read more: A nascent Indian e-pharma sector already plagued by bias and harassment

Pharma Reviews: #dnaEdit: Modi govt's ambitious FDI push

The cautious FDI policy has been counterproductive, except in pharma where India can truly boast of a robust domestic industry which supplies cheap ...
Read more: #dnaEdit: Modi govt's ambitious FDI push

Pharma Reviews: China rolls out sops for investments to Indian pharma companies

MUMBAI: China, the second largest pharmaceutical market in the world after US, is luring Indian drug companies to set up greenfield operations in ...
Read more: China rolls out sops for investments to Indian pharma companies

Pharma Reviews: Cong smells defaulter plot

Spokesperson Anand Sharma said: "100 per cent FDI in pharmaceuticals ... pre-conditions had been put in place to help the Indian pharma industry.
Read more: Cong smells defaulter plot

Pharma Reviews: Shot in the arm for pharma

Shot in the arm for pharma ... over foreign players controlling the market for vital drugs through mergers and acquisitions of Indian pharma companies.
Read more: Shot in the arm for pharma

Pharma Reviews: Pharma biggies among 200 under lens for poor drugs

New Delhi: The Drug Controller General of India has launched inspections against 200 drugmakers, including leading firms like Cipla and Pfizer, ...
Read more: Pharma biggies among 200 under lens for poor drugs

Pharma Reviews: Airlines, pharma firms to see funds infusion; little change in retail sector

The Centre is attempting to make the best use of the positive investment sentiment towards India by easing FDI restrictions in a number of sectors.
Read more: Airlines, pharma firms to see funds infusion; little change in retail sector

Pharma Reviews: Pharma sector: green shoots for brownfield projects

The domestic industry also hailed the move. “FDI will favourably impact the Indian pharmaceutical industry by providing access to more capital/funds ...
Read more: Pharma sector: green shoots for brownfield projects

Pharma Reviews: FDI norms relaxation a long-awaited reform: Shaw

Relaxing Foreign Direct Investment (FDI) norms in pharmaceutical industry is welcome and a long-awaited reform, said leading Indian biotech ...
Read more: FDI norms relaxation a long-awaited reform: Shaw

Pharma Reviews: Easing FDI norm will see more M&A deals in pharma: Experts

"Further relaxation of FDI norms in the pharma sector is a good move, as it ... Some Indian pharma companies were looking at raising funds from QIP ...
Read more: Easing FDI norm will see more M&A deals in pharma: Experts

Pharma Reviews: FDI reform a 'betrayal' to local businessmen: RSS-affiliate

“Opening up sectors like retail, defence and pharma to FDI and by relaxing ... “The decision is against the public health of not just India but many ...
Read more: FDI reform a 'betrayal' to local businessmen: RSS-affiliate

Pharma Reviews: Pharma Stocks Climb Up To 10% On FDI Reforms

Press Trust of India | Last Updated: June 20, 2016 20:47 (IST) ... The market size of the country's pharma industry is estimated at over $20 billion.
Read more: Pharma Stocks Climb Up To 10% On FDI Reforms

Pharma Reviews: FDI reforms: RSS-affiliate decries govt move

"Opening up sectors like retail, defence and pharma to FDI and by relaxing norms is ... "They (foreign players) should only be allowed in greenfield pharma projects," he said, adding the edge the Indian pharma industry has in ...
Read more: FDI reforms: RSS-affiliate decries govt move

Pharma Reviews: FDI norms relaxation a long-awaited reform: Shaw

According to Shaw, Indian pharmaceutical industry is a global player with nearly 75 to 80 per cent of the industry's production ending up in exports.
Read more: FDI norms relaxation a long-awaited reform: Shaw

Pharma Reviews: New FDI norms welcome, but policy still needs to be put to test, say pharma companies

The new policy on foreign direct investment (FDI) announced by the government on Monday, June 20, has been welcomed by the Indian pharma ...
Read more: New FDI norms welcome, but policy still needs to be put to test, say pharma companies

Pharma Reviews: M&As ka Side Effects

Indian pharma companies have notched up some aggressive global buys recently but the sector's experience with cross border M&As has been mixed ...
Read more: M&As ka Side Effects

Pharma Reviews: 2nd wave of FDI reforms in aviation, pharma, defence

"Now most of the sectors would be under automatic approval route, except a small negative list. With these changes, India is now the most open ...
Read more: 2nd wave of FDI reforms in aviation, pharma, defence

Pharma Reviews: FDI up to 74% in brownfield pharma under automatic route

However, FDI in brownfield projects has been a contentious issue as concerns have been raised over some M&As of Indian pharma companies by ...
Read more: FDI up to 74% in brownfield pharma under automatic route

Pharma Reviews: Pharma Companies Hail New FDI Norms

Mumbai: The Organisation of Pharmaceutical Producers of India (OPPI) on Monday welcomed the Centre's decision to allow up to 74 per cent Foreign ...
Read more: Pharma Companies Hail New FDI Norms

Pharma Reviews: FDI up to 74% in brownfield pharma under automatic route

Under the existing policy on the sector, 100 per cent FDI is allowed under ... raised over some M&As of Indian pharma companies by foreign giants.
Read more: FDI up to 74% in brownfield pharma under automatic route

Pharma Reviews: 'India market is very important to us'

The number of Indian companies investing in Ireland through IDA Ireland ... company), I am confident of finding takers for any pharma manufacturing ...
Read more: 'India market is very important to us'

Pharma Reviews: ASSOCHAM lauds government's decision to relax FDI norms in key sectors

"FDI will favourably impact the Indian pharma industry by providing access to more capital/funds for investing in R&D, which in turn, leads to creation of ...
Read more: ASSOCHAM lauds government's decision to relax FDI norms in key sectors

Pharma Reviews: Betting big on M&As

These Indian pharma companies are cashing in on opportunities provided by mergers between their global peers. For instance, DRL's latest deals ...
Read more: Betting big on M&As

Pharma Reviews: FDI in pharma via automatic route a welcome step: Biocon

The government eased foreign direct investment in pharma sector and ... I think the pharma sector is a flagship sector for India and we should be far ...
Read more: FDI in pharma via automatic route a welcome step: Biocon

Pharma Reviews: Experts divided on benefits of easing FDI in brownfield pharma

said he does not see multinational companies (MNCs) making a beeline for entering the Indian pharma industry. They would still hesitate to come in, ...
Read more: Experts divided on benefits of easing FDI in brownfield pharma

Pharma Reviews: Govt bites FDI bullet, opens up defence, civil aviation and pharma

The extant FDI policy on pharmaceutical sector provides for 100% FDI ... of Indian companies operating scheduled and non-scheduled air-transport ...
Read more: Govt bites FDI bullet, opens up defence, civil aviation and pharma

Pharma Reviews: Cadila to set up 2k cr plant in Jhabua

INDORE: Giving a major boost to the tribal region of Jhabua district, Indian pharmaceutical giant 'Cadila Pharmaceuticals Limited' will soon be ...
Read more: Cadila to set up 2k cr plant in Jhabua

Pharma Reviews: PM Modi likely to chair meeting on FDI roadmap on Tuesday

FDI in the sector is a contentious issue as concerns have been raised over mergers and acquisitions of Indian pharma companies by foreign giants.
Read more: PM Modi likely to chair meeting on FDI roadmap on Tuesday

Pharma Jobs: pharmacist for Nalasopara

Company: AVS Manpower Consultancy Private Limited
Qualification: B.Pharm, Diploma
Experience: 2 to 5
location: Mumbai
Ref: 18875605
Summary: WE requrie urgently pharmacist for nalasopara good package.

Read more: pharmacist for Nalasopara

Pharma Jobs: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Company: Step Up Placements
Experience: 3 to 13
location: Berhampur, Ghaziabad
Ref: 18875939
Summary: On roll Job profile Please refer your friends also. We are dealing in all over India with MAX LIFE INSURANCE, KOTAK LIFE INSURANCE, BHARTI AXA LIFE INSURANCE, AVIVA LIFE INSURANCE and AEGON RELIGARE LIFE INSURANCE, Future....
Read more: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Pharma Jobs: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Company: Step Up Placements
Experience: 3 to 13
Salary: 1.20 to 4.00
location: Haldwani, Haridwar
Ref: 18875955
Summary: On roll Job profile Please refer your friends also. We are dealing in all over India with MAX LIFE INSURANCE, KOTAK LIFE INSURANCE, BHARTI AXA LIFE INSURANCE, AVIVA LIFE INSURANCE and AEGON....
Read more: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Pharma Jobs: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Company: Step Up Placements
Experience: 3 to 13
Salary: 1.20 to 4.00
location: Nashik, Ujjain
Ref: 18875590
Summary: On roll Job profile Please refer your friends also. We are dealing in all over India with MAX LIFE INSURANCE, KOTAK LIFE INSURANCE, BHARTI AXA LIFE INSURANCE, AVIVA LIFE INSURANCE and AEGON....
Read more: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Pharma Jobs: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Company: Step Up Placements
Experience: 3 to 13
Salary: 1.00 to 4.00
location: Jamnagar, Rajkot
Ref: 18875591
Summary: On roll Job profile Please refer your friends also. We are dealing in all over India with MAX LIFE INSURANCE, KOTAK LIFE INSURANCE, BHARTI AXA LIFE INSURANCE, AVIVA LIFE INSURANCE and AEGON....
Read more: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Pharma Jobs: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Company: Step Up Placements
Experience: 3 to 13
Salary: 1.00 to 4.00
location: Baroda / Vadodara, Surat
Ref: 18875625
Summary: On roll Job profile Please refer your friends also. We are dealing in all over India with MAX LIFE INSURANCE, KOTAK LIFE INSURANCE, BHARTI AXA LIFE INSURANCE, AVIVA LIFE INSURANCE and....
Read more: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Pharma Jobs: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Company: Step Up Placements
Experience: 3 to 13
Salary: 1.00 to 4.00
location: Kolhapur, Sangli
Ref: 18875653
Summary: On roll Job profile Please refer your friends also. We are dealing in all over India with MAX LIFE INSURANCE, KOTAK LIFE INSURANCE, BHARTI AXA LIFE INSURANCE, AVIVA LIFE INSURANCE and AEGON....
Read more: Urgent Job in MAX Life Insurance as Agency Development Manager (Tied/Agency Channel)

Pharma Reviews: Indian Pharmacovigilance Day 2016 to be observed in Mumbai on July 29

India is emerging as a target destination for procuring support services required for the global pharmaceutical industry, especially in ...
Read more: Indian Pharmacovigilance Day 2016 to be observed in Mumbai on July 29

Pharma Reviews: India's pharma exports may reach $20 bn by 2020: Study

Export of pharmaceutical products from India is likely to cross $14. billion (bn) mark this year and may reach about $20 bn by 2020, thereby registering ...
Read more: India's pharma exports may reach $20 bn by 2020: Study

Pharma Reviews: India's pharma exports may reach $20 bn by 2020:

“Consolidation of pharmacy players is leading to an increase in pricing pressures for generic companies existing in the US market which is expected ...
Read more: India's pharma exports may reach $20 bn by 2020:

Pharma Reviews: Indian pharmaceutical exports to cross $20 billion by 2020: Study

New Delhi, June 16 (IANS) Indian pharmaceutical exports are likely to cross $20 billion by 2020 from $14 billion in 2016, by registering a compounded ...
Read more: Indian pharmaceutical exports to cross $20 billion by 2020: Study

Pharma Reviews: Indian pharmaceutical exports to cross $20 billion by 2020: Study

Indian pharmaceutical exports are likely to cross $20 billion by 2020 from $14 billion in 2016, by registering a compounded annual growth rate ...
Read more: Indian pharmaceutical exports to cross $20 billion by 2020: Study

Pharma Reviews: 'Pharmalytics is an end-to-end analytics platform providing localised data of the demand and ...

What are the challenges in the pharma industry that CareOnGo seeks to ... How receptive is the Indian pharma industry towards new technologies?
Read more: 'Pharmalytics is an end-to-end analytics platform providing localised data of the demand and ...

Pharma Reviews: Pharma exporters hope for a barter-deal with African nations to beat currency blues

Pharma exporters from India hoping for a barter deal to be worked out with countries in Africa as well as some Latin ... Industry sources claimed that the payments of exporters, most of whom are small and medium sized players, are ...
Read more: Pharma exporters hope for a barter-deal with African nations to beat currency blues

Pharma Reviews: Indian Pharma Tycoons Foray Into New Drugs To Shore Up Growth

The U.S. patent on the device, called the Diskus inhaler, expires this year and some of India's leading drug companies want a piece of the treatment's ...
Read more: Indian Pharma Tycoons Foray Into New Drugs To Shore Up Growth

Pharma Reviews: Pharmexcil to compile document on India's pharma exports to Europe in next 4 yrs

Keen to boost India's market share in Europe, Pharmexcil is planning to start its work on compiling a document forecasting India's possible ...
Read more: Pharmexcil to compile document on India's pharma exports to Europe in next 4 yrs

US FDA News: Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication - Strengthened Kidney Warnings

Revised warnings in the drug labels to include information about acute kidney injury and added recommendations to minimize this risk.
Read more: Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication - Strengthened Kidney Warnings

US FDA News: FDA approves AspireAssist obesity device

The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion of the stomach contents after every meal.
Read more: FDA approves AspireAssist obesity device

Pharma Reviews: Insights into​career opportunities in pharmacy

With India emerging as a global hub for manufacturing and clinical trials of new molecules, the pharmaceutical sector offers huge job opportunities in ...
Read more: Insights into​career opportunities in pharmacy

Pharma Reviews: Indian pharma tycoons foray into new drugs to shore up growth

Success at copying cancer therapies or injectable medicines promises greater profits overseas, and could drive India's family pharmaceutical ...
Read more: Indian pharma tycoons foray into new drugs to shore up growth

Pharma Reviews: Havells India and Aurobindo Pharma and Rajesh Exports to see some action today

Indian pharmaceutical major Aurobindo Pharma, which has crossed $2 billion revenue mark in FY16, is planning to step up the momentum this year ...
Read more: Havells India and Aurobindo Pharma and Rajesh Exports to see some action today

Pharma Reviews: Passage of GST Bill may help pharma sector to improve supply chain efficiency: Pednekar

Goods and services tax (GST) Bill, once passed by the parliament, will usher in significant improvement in Indian pharma industry's supply chain ...
Read more: Passage of GST Bill may help pharma sector to improve supply chain efficiency: Pednekar

Pharma Reviews: CDSCO working towards drafting new Drugs & Cosmetics Act, 2016

Moreover, for the government, pharmaceuticals is a priority sector and ... 2016 will also ensure complete compliance by the Indian pharma industry.
Read more: CDSCO working towards drafting new Drugs & Cosmetics Act, 2016

Pharma Reviews: Lot of sovereign wealth funds looking into India and flows are going to increase: Sunil Singhania ...

Today if we discussed the Market action, looks like there is no worry in the ..... On the international side, the Indian pharma industry has made a new ...
Read more: Lot of sovereign wealth funds looking into India and flows are going to increase: Sunil Singhania ...

Pharma Reviews: Mark the stocks of Indian firms that are getting jittery about Brexit vote

A number of Indian companies, including IT services and pharma companies, use the UK as a hub to gain access to and expand in the rest of Europe.
Read more: Mark the stocks of Indian firms that are getting jittery about Brexit vote

Pharma Reviews: Pharma sector grows 7.7% in May; FDC ban weighs

Indian pharmaceutical market grew 7.7 percent in May compared with 3.5 percent in April, but the ban on fixed-dose combination (FDC) drugs remains ...
Read more: Pharma sector grows 7.7% in May; FDC ban weighs

Pharma Reviews: Indian pharma takes M&A route to build a global footprint

Ranbaxy alone took $3.2 billion for Sun Pharma, the largest transaction in the Indian industry. Not to be left out, Lupin struck the biggest deal last year ...
Read more: Indian pharma takes M&A route to build a global footprint

Pharma Reviews: Drug MNCs lobby for easier entry rule

New Delhi, June 12: Lobbying by multinational pharmaceutical giants for automatic approval to acquire 49 per cent in Indian companies has ...
Read more: Drug MNCs lobby for easier entry rule

Pharma Reviews: India-US ties: Enduring illusions of our times

Besides challenging India's patent regime, there were attempts to cripple Indian pharma companies and drive their drugs out of the US market.
Read more: India-US ties: Enduring illusions of our times

Pharma Reviews: Pharma sector grows 7.7% in May; FDC ban weighs

Indian pharmaceutical market grew 7.7 per cent in May compared with 3.5 per cent in April, but the ban on fixed-dose combination (FDC) drugs ...
Read more: Pharma sector grows 7.7% in May; FDC ban weighs

Pharma Reviews: Pharma sector grows 7.7 per cent in May; FDC ban weighs

MUMBAI: Indian pharmaceutical market grew 7.7 per cent in May compared with 3.5 per cent in April, but the ban on fixed-dose combination (FDC) ...
Read more: Pharma sector grows 7.7 per cent in May; FDC ban weighs

Pharma Reviews: Pharma sector grows 7.7% in May; FDC ban weighs

Indian pharmaceutical market grew 7.7% in May compared with 3.5% in April, but the ban on fixed-dose combination (FDC) drugs remains an ...
Read more: Pharma sector grows 7.7% in May; FDC ban weighs

Pharma Reviews: Ban on FDC drugs hurts growth of pharma industry

Even as the Indian pharma market clocked the lowest growth rate in two years in May this year (at 7.7 per cent) thanks to the ban on around 350 fixed ...
Read more: Ban on FDC drugs hurts growth of pharma industry

Pharma Reviews: India calls for flexibilities in intellectual property rights to combat AIDS

“We are well aware of the role that generic pharmaceutical manufacturers from India have played in initiating ARV treatment for over 17 million people ...
Read more: India calls for flexibilities in intellectual property rights to combat AIDS

Pharma Reviews: FDC ban hits pharma growth in May; industry not hopeful of a recovery soon

Even as the Indian pharma market clocked the lowest growth rate in two years in May this year (at 7.7%) thanks to the ban on around 350 fixed dose ...
Read more: FDC ban hits pharma growth in May; industry not hopeful of a recovery soon

Pharma Reviews: Indian pharma market posts 7.7% growth in May 2016 at

AIOCD Pharmasofttech AWACS report points out that the Indian Pharmaceutical Market (IPM) has posted growth of 7.7 per cent during May 2016 at ...
Read more: Indian pharma market posts 7.7% growth in May 2016 at

Pharma Reviews: India supplying over 80% of drugs to combat AIDS: Nadda

Over 80 per cent of the drugs used globally to combat the deadly AIDS virus are supplied by Indian pharmaceutical firms, and the low-cost generic ...
Read more: India supplying over 80% of drugs to combat AIDS: Nadda

US FDA News: FDA approves vaccine to prevent cholera for travelers

The U.S. Food and Drug Administration today approved Vaxchora, a vaccine for the prevention of cholera caused by serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas. Vaxchora is the only FDA-approved vaccine for the prevention of cholera.
Read more: FDA approves vaccine to prevent cholera for travelers

Pharma Reviews: CPhI's 5th Annual InnoPack Pharma Confex Concludes on a High Note

CPhI Conferences, a division of UBM India which hosts a number of successful pharmaceutical conferences concluded its 5th Annual InnoPack ...
Read more: CPhI's 5th Annual InnoPack Pharma Confex Concludes on a High Note

Pharma Reviews: India calls for flexibilities in intellectual property rights to combat AIDS

"We are well aware of the role that generic pharmaceutical manufacturers from India have played in initiating ARV treatment for over 17 million people ...
Read more: India calls for flexibilities in intellectual property rights to combat AIDS

Pharma Reviews: India calls for flexibilities in IPR to combat AIDS

"We are well aware of the role that generic pharmaceutical manufacturers from India have played in initiating antiretroviral (ARV) treatment for over 17 ...
Read more: India calls for flexibilities in IPR to combat AIDS

Pharma Reviews: Jaitley proposes to allow direct FDI in pharma sector; domestic companies worry over M&As

The report said FDI in the sector is a contentious issue as there are concerns over mergers and acquisitions of Indian pharma companies by their ...
Read more: Jaitley proposes to allow direct FDI in pharma sector; domestic companies worry over M&As

Pharma Reviews: 'Indian pharma leading global fight against HIV'

The low-cost generic medicines produced by the Indian pharmaceutical industry have been instrumental in scaling up access to HIV treatment not only ...
Read more: 'Indian pharma leading global fight against HIV'

Pharma Reviews: Government may relax FDI norms in brownfield pharma companies

FDI in the sector is a contentious issue as concerns have been raised over some mergers and acquisitions of Indian pharma companies by foreign ...
Read more: Government may relax FDI norms in brownfield pharma companies

Pharma Reviews: India's pharma market dips to a 2-year low in May

NEW DELHI: The Indian pharmaceuticals market's growth this May has been the lowest in two years, impacted by a drop in sales of fixed dose ...
Read more: India's pharma market dips to a 2-year low in May

Pharma Reviews: Govt weighs relaxing FDI norms in brownfield pharma cos

India is recognised as a major generic medicine hub of the world. The market size of the country's pharma industry is estimated at over USD 20 billion.
Read more: Govt weighs relaxing FDI norms in brownfield pharma cos

US FDA News: FDA targets unlawful internet sales of illegal prescription medicines during International Operation Pangea IX

The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 websites that illegally sell potentially dangerous, unapproved prescription drugs to U.S. consumers. This effort was part of Operation Pangea IX, the Ninth Annual International Internet Week of Action (IIWA), a global cooperative effort, led by INTERPOL, to combat the unlawful sale and distribution of illegal and potentially counterfeit medical products on the internet.
Read more: FDA targets unlawful internet sales of illegal prescription medicines during International Operation Pangea IX

US FDA News: Statement on HHS OIG Early Alert on FDA food recall initiation process

Public health is our top priority and the U.S. Food and Drug Administration works hard to ensure the U.S. food supply remains among the safest in the world.
Read more: Statement on HHS OIG Early Alert on FDA food recall initiation process

Pharma Reviews: OPPI facilitates a panel discussion on National IPR Policy

As part of its Golden Jubilee Celebration and in line with the theme of 'Healthy India, Innovative India', the Organisation of Pharmaceutical Producers ...
Read more: OPPI facilitates a panel discussion on National IPR Policy

Pharma Reviews: Indian pharma leading global fight against HIV: Nadda at UNGA

More than 80 per cent of the low-cost drugs used to combat the HIV globally are manufactured in India and have helped scale up access to treatment ...
Read more: Indian pharma leading global fight against HIV: Nadda at UNGA

Pharma Reviews: 80% drugs to combat AIDS globally supplied by India: Health minister

India has said that over 80%of the drugs used globally to combat the deadly AIDS are supplied by Indian pharmaceutical firms and the low-cost ...
Read more: 80% drugs to combat AIDS globally supplied by India: Health minister

Pharma Reviews: 80% drugs to combat AIDS supplied by India: JP Nadda

UNITED NATIONS: India has said that over 80 per cent of the drugs used globally to combat the deadly AIDS are supplied by Indian pharmaceutical ...
Read more: 80% drugs to combat AIDS supplied by India: JP Nadda

Pharma Reviews: 80% drugs to combat AIDS supplied by India: Nadda

India has said that over 80 per cent of the drugs used globally to combat the deadly AIDS are supplied by Indian pharmaceutical firms and the low-cost ...
Read more: 80% drugs to combat AIDS supplied by India: Nadda

Pharma Reviews: UN declaration backs India's policy on generic HIV/AIDS medicines

More than 80 percent of the antiretroviral drugs for treating HIV/AIDS are supplied by the Indian pharmaceutical industry and they have helped save ...
Read more: UN declaration backs India's policy on generic HIV/AIDS medicines

Pharma Reviews: IPR Policy falls short of policy integration and implementation strategy: Experts

The experts addressing a panel discussion held by Organisation of Pharmaceutical Producers of India (OPPI) in Mumbai said the intention of the ...
Read more: IPR Policy falls short of policy integration and implementation strategy: Experts

Pharma Reviews: Industry wants Centre to increase validity of WHO GMP certification from 2 to 5 years

The Indian Drug Manufacturers' Association- Gujarat State Board (IDMA-GSB) is actively pushing for extension of the WHO GMP certification from 2 ...
Read more: Industry wants Centre to increase validity of WHO GMP certification from 2 to 5 years

US FDA News: Nature Made (Various Products) by Pharmavite LLC: Recall - Possible Health Risk

Salmonella can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.
Read more: Nature Made (Various Products) by Pharmavite LLC: Recall - Possible Health Risk

Pharma Reviews: Time to do more to retain ownership of US market: Dilip Shanghvi

Over the last year, regulatory hassles have made US market tougher to navigate for Indian companies. Sun Pharmaceutical MD Dilip Shanghvi, ...
Read more: Time to do more to retain ownership of US market: Dilip Shanghvi

Pharma Reviews: SHIFTING TO VEG CAPSULES

As expected, the reactions from the pharmaceutical industry on the matter has been largely negative. Two major industry bodies namely Indian Drug ...
Read more: SHIFTING TO VEG CAPSULES

US FDA News: Step 2 60 Gold by The Body Shot Bar: Recall - Undeclared Drug Ingredients

Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
Read more: Step 2 60 Gold by The Body Shot Bar: Recall - Undeclared Drug Ingredients

US FDA News: Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse

Majority of reported problems occurred in individuals intentionally misusing and abusing high doses of loperamide in attempts to self-treat opioid withdrawal symptoms or to achieve a feeling of euphoria.
Read more: Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse

Pharma Reviews: Why Narendra Modi's US visits make the sick and poor in India anxious

Had the 2015 decision stayed, Indian companies could have manufactured the drug locally and made it available at a fraction of its original cost. In the ...
Read more: Why Narendra Modi's US visits make the sick and poor in India anxious

Pharma Reviews: Pharma Stocks Look Attractive After Correction: Chintan Haria

The fund manager said Indian pharma companies have established their ... Other than pharma shares, Mr Haria is also bullish on oil & gas shares.
Read more: Pharma Stocks Look Attractive After Correction: Chintan Haria

Pharma Reviews: Pharma firms to step up R&D spending

Aggregate R&D spends of the top few companies in domestic pharma ... However ICRA expects the growth trajectory for Indian pharma to moderate, ...
Read more: Pharma firms to step up R&D spending

US FDA News: Over-the-Counter Antacid Products Containing Aspirin: FDA Drug Safety Communication - Serious Bleeding Risk

Risk of serious bleeding when using nonprescription, also known as over-the-counter or OTC, aspirin-containing antacid products.
Read more: Over-the-Counter Antacid Products Containing Aspirin: FDA Drug Safety Communication - Serious Bleeding Risk

Pharma Reviews: Pharma companies step up R&D spend, focus on specialty drugs

Sun Pharma's R&D spend rose 23% to 9.1% of sales in Q4 FY16 on a ... However, ICRA expects growth trajectory for Indian pharmaceutical industry ...
Read more: Pharma companies step up R&D spend, focus on specialty drugs

Pharma Reviews: End Protectionism To Remove Hurdles In Indo-US Trade, Says Rajnath Singh

Protectionism is one the biggest hurdles between India and US trade ... Mr Singh said the US can take the advantage of Indian pharma industry's ...
Read more: End Protectionism To Remove Hurdles In Indo-US Trade, Says Rajnath Singh

Pharma Reviews: Torrent Pharma plans 50% hike in R&D spend, focuses on regulated mkts

Torrent is one of the few Indian pharma companies to have met all compliance standards of the US Food and Drug Administration (FDA), the sector ...
Read more: Torrent Pharma plans 50% hike in R&D spend, focuses on regulated mkts

Pharma Reviews: Indian-origin brothers get caught in UK pharma imbroglio

LONDON: Two Indian-origin millionaire brothers were today caught in a ... Bhikhu and Vijay Patel, the founders of pharmaceutical empire Waymade ...
Read more: Indian-origin brothers get caught in UK pharma imbroglio

Pharma Reviews: End protectionism to remove hurdles in Indo-US trade: Rajnath

Of late, the industry has been accusing the US and other developed nations ... Singh said the US can take the advantage of Indian pharma industry's ...
Read more: End protectionism to remove hurdles in Indo-US trade: Rajnath

Pharma Reviews: MFs' favorites: Bank, Software and Pharma stocks attract maximum fund deployment

Despite mounting NPAs taking a massive toll on the Indian banking sector, MFs still seem bullish on bank stocks. It is pertinent to note that since ...
Read more: MFs' favorites: Bank, Software and Pharma stocks attract maximum fund deployment

Pharma Reviews: End protectionism to remove hurdles in Indo-US trade: Rajnath

Protectionism is one the biggest hurdles between India and US trade ... Singh said the US can take the advantage of Indian pharma industry's success ...
Read more: End protectionism to remove hurdles in Indo-US trade: Rajnath

Pharma Reviews: Indian-origin brothers caught up in UK pharma scandal: Report

Bhikhu and Vijay Patel, the founders of pharmaceutical empire Waymade Plc, have been named in a special 'Times' investigation for charging ...
Read more: Indian-origin brothers caught up in UK pharma scandal: Report

Pharma Reviews: Going Green

Though the government is encouraging pharma companies to explore less accessed zones across India, it also expects companies to adhere to ...
Read more: Going Green

Pharma Reviews: End protectionism to remove hurdles in Indo-US trade: Home Minister

The minister hoped bilateral trade between India and the US to touch USD ... Singh said the US can take the advantage of Indian pharma industry's ...
Read more: End protectionism to remove hurdles in Indo-US trade: Home Minister

Pharma Reviews: Net loss of 11 Sensex heavyweights higher than net profit of 16 bluechips

The Indian banking sector struggled to avert the rising NPAs; while the pharmaceutical industry faced regulatory actions by the US and EU regulators.
Read more: Net loss of 11 Sensex heavyweights higher than net profit of 16 bluechips

Pharma Reviews: US industry sends list of complaints to Obama ahead of Modi's visit

So, what are the big concerns and what is it that the US pharma industry in particular, would like India to do? One issue is unhappiness with India's ...
Read more: US industry sends list of complaints to Obama ahead of Modi's visit

Pharma Reviews: Pharma cos to see moderation in growth in US market: Icra

New Delhi, Jun 2 () Indian drug industry will see moderation in growth due to slowing of business in the US market with reduction in the number of ...
Read more: Pharma cos to see moderation in growth in US market: Icra

Pharma Reviews: Indian drug cos grow slow in the US and other top pharma news

The Indian drug industry will see moderation in growth due to slowing of business in the US market with reduction in the number of large size drugs ...
Read more: Indian drug cos grow slow in the US and other top pharma news

Pharma Reviews: Sanofi India names Aditya Narayan as the Chairman of the Board of Directors

Sanofi India Ltd, the Indian arm of the French pharma major Sanofi SA has ... Aditya Narayan, 64, has rich experience in industry for over 40 years.
Read more: Sanofi India names Aditya Narayan as the Chairman of the Board of Directors

Pharma Reviews: Pharma industry & researchers familiar with HPMC feel confident of veg capsule safety parameters

With the Indian pharma associations like IDMA and CIPI approaching the Drugs Control General of India (DCGI) not to substitute gelatin capsules with ...
Read more: Pharma industry & researchers familiar with HPMC feel confident of veg capsule safety parameters

Pharma Reviews: Doing business in the US pharma market has become more expensive & challenging for Indian ...

ET Intelligence Group : One of the disappointing features of the Q4 earnings season was the under-performance of pharma companies. Leading drug ...
Read more: Doing business in the US pharma market has become more expensive & challenging for Indian ...

Pharma Reviews: Indian pharma industry's growth may slow down: ICRA

The Indian pharmaceutical companies have registered strong growth over last decade driven mainly by US market with CAGR of revenue growth from ...
Read more: Indian pharma industry's growth may slow down: ICRA

US FDA News: Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars

Reports of severe redness, pain, skin discoloration, blistering, and cracked skin.
Read more: Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars

Pharma Reviews: Pharma companies to see moderation in growth in US market: ICRA

Indian drug industry will see moderation in growth due to slowing of business in the US market with reduction in the number of large size drugs going ...
Read more: Pharma companies to see moderation in growth in US market: ICRA

Pharma Reviews: Pharma Companies To See Moderation In Growth In US Market: Icra

New Delhi: Indian drug industry will see moderation in growth due to slowing of business in the US market with reduction in the number of large size ...
Read more: Pharma Companies To See Moderation In Growth In US Market: Icra

US FDA News: Statement from FDA Commissioner Robert Califf, M.D. on the release of the final individual patient expanded access form

Today, the U.S. Food and Drug Administration finalized its efforts to streamline the process used by physicians to request expanded access, often called “compassionate use,” to investigational drugs and biologics for their patients. As a physician, I understand the importance of being able to access investigational treatments for a patient when there are no other options to treat their serious disease or condition.
Read more: Statement from FDA Commissioner Robert Califf, M.D. on the release of the final individual patient expanded access form

Pharma Reviews: Experts urge India to join PIC/S to enhance recognition & sustain India's global leadership in ...

India is only eligible to be an observer initially, till the regulatory system ... Consequently, the pharmaceutical industry located in these countries ...
Read more: Experts urge India to join PIC/S to enhance recognition & sustain India's global leadership in ...

US FDA News: FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors

The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs).
Read more: FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors

US FDA News: FDA takes action against Kansas food manufacturer for repeated food safety violations

The U.S. District Court for the District of Kansas entered a consent decree of permanent injunction today between the United States and Native American Enterprises, LLC, located in Wichita, Kansas; its part-owner, William N. McGreevy; and its production manager, Robert C. Conner.
Read more: FDA takes action against Kansas food manufacturer for repeated food safety violations

US FDA News: FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. Such mutations are present in approximately 10-20 percent of non-small cell lung cancers (NSCLC).
Read more: FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer

US FDA News: Stӧckert 3T Heater-Cooler System by Sorin Group Deustchland GmbH: Safety Communication - Reports of Mycobacterium Chimaera Infections

There may be a higher risk of patient infection associated with surgeries that introduced a prosthetic product/material [e.g., heart valve, graft, LVAD], or heart transplants when the 3T was used.
Read more: Stӧckert 3T Heater-Cooler System by Sorin Group Deustchland GmbH: Safety Communication - Reports of Mycobacterium Chimaera Infections

US FDA News: FDA issues draft guidance to food industry for voluntarily reducing sodium in processed and commercially prepared food

Today, the U.S. Food and Drug Administration issued draft guidance for public comment that provides practical, voluntary sodium reduction targets for the food industry. Average sodium intake in the U.S. is approximately 3,400 mg/day. The draft short-term (two-year) and long-term (10-year) voluntary targets for industry are intended to help the American public gradually reduce sodium intake to 2,300 milligrams (mg) per day, a level recommended by leading experts and the overwhelming body of scientific evidence. The targets are also intended to complement many existing efforts by food manufacturers, restaurants, and food service operations to reduce sodium in foods.
Read more: FDA issues draft guidance to food industry for voluntarily reducing sodium in processed and commercially prepared food

Pharma Reviews: CIPI asks DCGI to rollback decision on cellulose based capsules

Concerned over the quality, safety and high cost of cellulose based capsules, the Confederation of Indian Pharmaceutical Industry (CIPI) has urged ...
Read more: CIPI asks DCGI to rollback decision on cellulose based capsules

Pharma Reviews: US FDA troubles for pharma space nearing an end: MS

India's pharma sector which just seems to be coming out of overhang related to US FDA regulations is a good bet and the US market is a good place ...
Read more: US FDA troubles for pharma space nearing an end: MS

Pharma Reviews: Time for India to be innovator nation in bio-pharma: Expert

Observing India's potential, Michael Rosenblatt, executive vice president of Merck & Co, one of the world's largest pharmaceutical companies, said ...
Read more: Time for India to be innovator nation in bio-pharma: Expert